Ascendis Pharma AS (NAS:ASND)
$ 151.26 -2.17 (-1.41%) Market Cap: 8.67 Bil Enterprise Value: 9.12 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Ascendis Pharma A/S - Special Call Transcript

Jun 26, 2019 / 01:00PM GMT
Release Date Price: $108.88 (-9.76%)
Scott T. Smith;S;CFO;Jan MÃ;ller
Ascendis Pharma A;Senior VP & Member of Executive Board

/- -

Okay. We're going to get started. Thanks, everyone for joining us. I'm Scott Smith, Chief Financial Officer of Ascendis.

As you might have expected, we'll be making some forward-looking statements. Please refer to our SEC filings for the associated risk factors. And here's the agenda. So first of all, I'd like to say welcome to everyone. Thanks for coming. Thanks for giving us the opportunity to present to you, the investment community, Ascendis Pharma, our current pipelines and future pipeline.

We have an action-packed agenda today. And as a lot of you know, we have a very strong German contingent at Ascendis. So we'll try to stay right on time. So we'll stick as closely as we can to the schedule. From a housekeeping item perspective, if you can just make sure to mute your cell phones. That would be appreciated.

And I think with that, I will turn it over to Jan to give a more detailed introduction.

¸

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot